-
ENHERTU® Approved in the EU as the First HER2 Directed Therapy for Patients with HER2 Low Metastatic Breast CancerDaiichi Sankyo2023-01-31 12:28:25ENHERTU® Approved in the EU as the First HER2 Directed Therapy for Patients with HER2 Low Metastatic Breast
-
ENHERTU® Type II Variation Application Validated by EMA for the Treatment of HER2 Mutant Metastatic Non-Small Cell Lung CancerDaiichi Sankyo2023-01-04 14:32:17ENHERTU® Type II Variation Application Validated by EMA for the Treatment of HER2 Mutant Metastatic Non-Small
-
ENHERTU® Recommended for Approval in the EU by CHMP for Patients with HER2 Low Metastatic Breast CancerDaiichi Sankyo2022-12-19 14:32:49ENHERTU® Recommended for Approval in the EU by CHMP for Patients with HER2 Low Metastatic Breast Cancer
-
ENHERTU® Approved in the EU for Patients with Previously Treated HER2 Positive Advanced Gastric CancerDaiichi Sankyo2022-12-19 14:33:43ENHERTU® Approved in the EU for Patients with Previously Treated HER2 Positive Advanced Gastric Cancer
-
Datopotamab Deruxtecan Showed Promising Responses as Monotherapy and in Combination with Durvalumab in Patients with Metastatic Triple Negative Breast Cancer in Two Early TrialsDaiichi Sankyo2022-12-09 10:52:07Datopotamab Deruxtecan Showed Promising Responses as Monotherapy and in Combination with Durvalumab in
-
Datopotamab Deruxtecan Showed Encouraging and Durable Efficacy in Patients with Heavily Pretreated HR Positive, HER2 Low or Negative Metastatic Breast CancerDaiichi Sankyo2022-12-09 10:53:06Datopotamab Deruxtecan Showed Encouraging and Durable Efficacy in Patients with Heavily Pretreated HR
-
ENHERTU® Achieved Statistically Significant Overall Survival Reducing the Risk of Death by 36% Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer in DESTINY-Breast03Daiichi Sankyo2022-12-08 13:03:04ENHERTU® Achieved Statistically Significant Overall Survival Reducing the Risk of Death by 36% Versus
-
Primary endpoint met in the CLEAR Outcomes Trial of bempedoic acid showing statistically significant relative risk reduction in major adverse CV eventsDaiichi Sankyo2022-12-08 10:41:45Primary endpoint met in the CLEAR Outcomes Trial of bempedoic acid showing statistically significant relative
-
Latest simulation analyses from the SANTORINI registry indicates that adding bempedoic acid in the lipid lowering treatment algorithm might help more patients achieve LDL-C recommended goalsDaiichi Sankyo2022-09-06 16:43:43Latest simulation analyses from the SANTORINI registry indicates that adding bempedoic acid in the lipid
-
New data further strengthens important role of LIXIANA® (edoxaban) in managing complex patient populations with atrial fibrillation (AF)Daiichi Sankyo2022-09-06 16:40:26New data further strengthens important role of LIXIANA® (edoxaban) in managing complex patient populations
